Search the Newsreel

Ellomay Capital Ltd (ELLO) Q3 2024 Earnings: Profitability Achieved Amid Market Uncertainty - Guidance Downgrade Alert

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 17.2% - Here's Why

Lockheed Martin (LMT) Stock May Be Below Fair Value On $10.5B Logistics Win

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Lockheed Martin stock has returned 58.4% over the past five years, and today the valuation checks point to a different kind of interest, with both the Discounted …

BHC5652799 Bond Profile — Key Metrics

This article provides key metrics for the Bausch + Lomb Corporation 8.375% 01-OCT-2028 bond (BHC5652799). It details the issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. The profile also includes a description of Bausch + Lomb's business segments, covering Vision …

J.P. Morgan Maintains Palomar Holdings(PLMR.US) With Buy Rating, Raises Target Price to $167

J.P. Morgan has reiterated its Buy rating for Palomar Holdings (PLMR.US) and increased the target price to $167. This indicates an optimistic outlook from the firm regarding Palomar Holdings' future performance.

Palomar Holdings (PLMR) Stock Trades Up, Here Is Why

Shares of Palomar Holdings (PLMR) increased by 4.1% after JP Morgan analyst Pablo S. Singzon maintained an Overweight rating and raised the price target from $150 to $167. This positive analyst action signaled strong conviction in the company's prospects, driving investor interest. Despite a …

Loma Negra stock holds as investors await fresh data

Loma Negra (US54150E1047) stock remains stable, with the company's core business still centered on Cement, Concrete, and Lime in Argentina. Investors are awaiting new financial data to assess revenue, EBITDA, and cash generation as no current market price or detailed financial figures were available …

(PLMR) Volatility Zones as Tactical Triggers

Stock Traders Daily provides a detailed analysis of Palomar Holdings Inc. (NASDAQ: PLMR), identifying neutral near-term readings despite strong mid-term sentiment potentially stalling. The report outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. Key …

Bausch + Lomb's Prescription Drug Growth Could Support Q2 Results, RBC Says

RBC Capital Markets highlighted that Bausch + Lomb's prescription drug segment is a key growth driver that could positively impact its second-quarter results. Strong performance in this division, particularly with products like Miebo and other ophthalmology treatments, is expected to help the company meet …

PLMR Maintained by JP Morgan -- Price Target Raised to $167.00

JP Morgan has maintained an Overweight rating for Palomar Holdings Inc (PLMR), raising its price target from $150.00 to $167.00, reflecting confidence in the company's growth. GuruFocus indicates that PLMR is currently undervalued by 8.0%, with a GF Value™ of $152.10 against a current …

Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S.

Bausch + Lomb BLCO recently announced the U.S. launch of the EyeGility Inserter, a preloaded intraocular lens (IOL) delivery system designed for its enVista family of IOLs. The system is now available for enVista Aspire preloaded IOLs, while enVista Envy lenses integrated with the …

Insights Into Lockheed (LMT) Q2: Wall Street Projections for Key Metrics

Wall Street analysts forecast that Lockheed Martin (LMT) will report quarterly earnings of $7.28 per share in its upcoming release, pointing to a year-over-year decline of 0.1%. It is anticipated that revenues will amount to $19.52 billion, exhibiting an increase of 7.5% compared to …

Lockheed Answers Cheap Drones With a Cheaper Interceptor

This article first appeared on GuruFocus. Lockheed Martin (NYSE:LMT) rose 0.26% in premarket after announcing a lower-cost Patriot missile aimed at countering drones, unveiled on the opening day of the Farnborough Airshow. The PAC-3 Adapted Capability Effector, or ACE, will cost less than half …

Lockheed Martin Unveils MORFIUS™ X-Rotor: The New Drone‑Killer Set to Power America's Fight Against Swarms

New airborne high power microwave counter‑drone system can neutralize more than 50 enemy drones in a single flight and be reused in the field FARNBOROUGH, England, July 20, 2026 /PRNewswire/ -- Commercial swarms of hostile drones are fast becoming the biggest threat to allied …

Lockheed Martin Introduces PAC-3 ACE™ - A High-Performance, Low-Cost Interceptor

PAC-3 ACE costs less than half of PAC-3 MSE FARNBOROUGH, England, July 20, 2026 /PRNewswire/ -- Lockheed Martin (NYSE: LMT) today announced the introduction of the PAC-3® Adapted Capability Effector (PAC-3 ACE™), a low-cost interceptor built to defeat a wide range of air and …

Gráfico y cotización de LOMA: NYSE:LOMA

This article provides a detailed overview of Loma Negra Compania Industrial Argentina Sociedad Anonima (NYSE: LOMA), including its stock performance, key financial statistics, and analyst ratings. It highlights that the company operates in the non-energetic minerals and construction materials sector, with a current market …

(LOMA) Movement Within Algorithmic Entry Frameworks

This article provides an algorithmic analysis of Loma Negra Compania Industrial Argentina Sociedad Anonima (NASDAQ: LOMA), indicating a neutral near and mid-term outlook but a positive long-term bias. It outlines three distinct AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and …

Bausch + Lomb (BLCO) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Bausch + Lomb (BLCO) presented at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026, outlining its strategic vision focused on selling excellence, operational reliability, R&D, and financial excellence. The company aims for 5-7% top-line growth and increased EBITDA margins from 17% to …

Form 4 Palomar Holdings Inc For: 17 July By Investing.com

This article announces the filing of Form 4 for Palomar Holdings Inc., dated July 17. The Form 4 is a document filed with the SEC to disclose changes in beneficial ownership of a company's securities by insiders. The article indicates a 0.90% increase in …

Palomar Holdings (PLMR) CEO acquires 118,750 shares via PSU and RSU vesting

Palomar Holdings CEO Mac Armstrong reported the vesting of 118,750 shares from Performance Share Units (PSUs) and Restricted Stock Units (RSUs) on July 15, 2026. Simultaneously, 60,741 shares valued at $131.66 each were automatically sold to cover tax withholding obligations. After these transactions, Armstrong …

Palomar Holdings, Inc. Revenue Breakdown – BIVA:PLMR

Palomar Holdings, Inc. (BIVA:PLMR) reported a total revenue of 36.56 billion MXN last year. The Earthquake segment was the top-performing contributor, generating 10.30 billion MXN, which was a decrease from 10.90 billion MXN in the previous year. All of the company's revenue came from …

ETFs Investing in Palomar Holdings, Inc. Stocks

This article lists various ETFs that invest in Palomar Holdings, Inc. stocks, providing key financial data for each fund, including market value, weight, issuer, management style, expense ratio, and recent performance. The ETFs primarily focus on small-cap and extended-market strategies, with some also targeting …

Palomar Holdings, Inc. Cash Flow – BMV:PLMR

Palomar Holdings, Inc. (BMV:PLMR) reported its financial performance, detailing free cash flow and operating cash flow. For Q1 2026, the free cash flow was 843.33 million MXN, while the entire year 2025 saw a free cash flow of 7.55 billion MXN and operating cash …

Bausch + Lomb launches EyeGility IOL delivery system in U.S.

Bausch + Lomb has launched its EyeGility Inserter preloaded IOL delivery system in the U.S., designed for the enVista family of intraocular lenses. This system offers one-handed operation and balanced push force for lens delivery through a small incision, improving surgical efficiency. The company's …

Bausch + Lomb's BL1107 falls short in phase 2 glaucoma trial, redirects program toward geographic atrophy implant

Bausch + Lomb announced that its BL1107 candidate failed to meet its primary endpoint in a phase 2 glaucoma trial, which aimed to replicate visual function improvements seen in an earlier phase 1/2a study. While the drug did achieve intraocular pressure reduction, it did …

Basic earnings per share (basic EPS) of Palomar Holdings, Inc. – BMV:PLMR

This article provides financial information for Palomar Holdings, Inc. (BMV:PLMR), specifically focusing on its basic earnings per share (basic EPS). It highlights key financial data available on TradingView for the Mexican Stock Exchange listing of Palomar Holdings.

Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $21

Goldman Sachs has reiterated a Hold rating on Bausch + Lomb Corp. (BLCO.US) stock. The firm also increased its price target for BLCO.US shares to $21. This indicates a continued cautious but slightly more optimistic outlook on the company's stock by Goldman Sachs.

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States

Bausch + Lomb has launched its EyeGility™ Inserter preloaded IOL delivery system in the U.S., designed for the enVista® family of intraocular lenses. This system offers convenient one-handed operation and balanced push force for smooth delivery, aiming to improve efficiency and comfort for surgeons. …

Bausch + Lomb launches EyeGility IOL delivery system in U.S. By Investing.com

Bausch + Lomb (NYSE/TSX:BLCO) has launched its EyeGility Inserter preloaded IOL delivery system in the U.S., designed for the enVista family of intraocular lenses. This system offers one-handed operation and is engineered for efficient lens delivery through a 2.4mm incision, with enVista Envy lenses …

Diversify Wealth Management LLC Makes New $1.05 Million Investment in Palomar Holdings, Inc. $PLMR

Diversify Wealth Management LLC has made a new investment of $1.05 million in Palomar Holdings, Inc. (NASDAQ:PLMR), acquiring 8,500 shares in the first quarter. Numerous other institutional investors also adjusted their holdings in Palomar. Meanwhile, company insiders sold a significant number of shares, while …

ICICI Lombard share price: Why this stock fell 15% today; target prices

ICICI Lombard Q1 Profit Falls 46%; BUY Rating Maintained

ICICI Lombard shares crash 13% as brokerages flag 'significant' fall in Q1 PAT

ICICI Lombard shares crash 15% after Q1 show. What should investors do?

India's ICICI Lombard loses over $980 mln in value on persistent earnings worries

Piper Sandler Maintains Palomar Holdings(PLMR.US) With Buy Rating, Raises Target Price to $165

Piper Sandler has reiterated its Buy rating on Palomar Holdings (PLMR.US) and increased its target price to $165. This indicates a continued positive outlook from the firm regarding Palomar Holdings' stock performance.